The new screening technique can scan thousands and even millions of compounds to identify those that activate dendritic cells, which are on constant recon patrol throughout the body to scout out cancerous or infected cells and alert the immune system.
"Our assay is unique from other conventional ones in its sensitivity and cost- and time-efficiency," said Dr. Akira Takashima, professor of dermatology and vice chairman for research and head of the project.
Dendritic cells (DCs) are considered key to developing future vaccines that can either mimic the body's natural immune response or turn on immune responses that failed - due, for example, to cancer or an immune deficiency.
The team, which also included Dr. Norikatsu Mitzumoto, assistant professor of dermatology and the study's lead author, and Drs. Hironori Matsushima and Hiroaki Tanaka, postdoctoral researchers in dermatology, created the cell-based biosensor system.
"We basically engineered DCs to express a fluorescent signal only when sensing activation signals so that you can identify immuno-stimulatory agents very easily," said Dr. Takashima. Immuno-stimulatory agents launch the immune system.
The research appears on Blood magazine's online Web site and will appear in a future issue.
"We have optimized the high-throughput screening capability - an experienced scientist can now test one thousand chemicals a day almost single-handedly," added Dr. Mizumoto. Previously, scientists would have to test each compound individually, a time-consuming process.
Their research already has led to the discovery of several compounds that turn on dendritic cells, which are found throughout the body from skin to blood. They continuously scan t
'"/>
Source:UT Southwestern Medical Center